Shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report) fell 10.9% during mid-day trading on Thursday. The company traded as low as $0.7617 and last traded at $0.7619. 49,939 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 8,800,836 shares. The stock had previously closed at $0.8548.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dermata Therapeutics in a research note on Monday, October 26th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.
View Our Latest Analysis on DRMA
Dermata Therapeutics Stock Performance
The stock has a market capitalization of $3.78 million, a P/E ratio of -0.17 and a beta of 0.63. The stock has a 50-day moving average price of $1.04 and a two-hundred day moving average price of $1.30.
Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.19).
About Dermata Therapeutics
Dermata Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for dermatological diseases. The company’s research is centered on topical therapies intended to address common inflammatory and dermatologic conditions.
Its lead product candidate, DMT310, is a once-weekly topical treatment being evaluated for conditions including psoriasis and acne vulgaris. The therapy is based on a proprietary platform derived from a naturally occurring freshwater sponge and is designed to deliver localized treatment to the skin.
Recommended Stories
- Five stocks we like better than Dermata Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
